Alterity Therapeutics Limited ATHE
Nov 5, 2026, 12:11 PM EST
- YTD
- -26.30%
- 1 year
- -41.79%
- Market cap
- 43.34M
- Revenue (ttm)
- 4.02M
- EPS (ttm)
- -0.90
- Shares out
- 8.74M
- Forward P/E
- -27.22
- YTD return
- -26.30%
- 1-year return
- -41.79%
- Volume
- 27.52K
- Avg volume
- 85.39K
- Open
- 2.35
- Previous close
- 2.44
- Day's range
- 2.17 – 2.58
- 52-week range
- 2.01 – 5.89
- Beta
- 0.68
- Analysts
- Buy
- Price target
- 8.00 (+252.4%)
5D +0.18 (+8.18%)
Key statistics
- Enterprise value
- 11.69B
- PEG ratio
- 0.00
- Price / sales
- 5.33
- Price / book
- 816.67
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 38.40%
- Free cash flow
- -5.36M
- Total cash
- 12.64M
- Total debt
- 159.04K
- Return on equity
- -104.47%
- Short % of float
- 0.02%
- 50-day average
- 1.48
- 200-day average
- 1.67
Analyst view
Consensus: buy
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 12, 2024 | Maxim Group | init | — | Buy |
| Mar 7, 2024 | Benchmark | reit | Speculative Buy | Speculative Buy |
| Jun 5, 2023 | Ladenburg Thalmann | main | Buy | Buy |
About Alterity Therapeutics Limited
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Australia
- Website
- alteritytherapeutics.com
News
Alterity Therapeutics Releases Appendix 4C – Q1 FY27 Quarterly Cash Flow Report & Corporate Update 
Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference 
Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson's Disease and Movement Disorders 
12 Health Care Stocks Moving In Friday's Pre-Market Session 
Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Stock Has Average Price Target of $10.00 - 12 Health Care Stocks Moving In Wednesday's After-Market Session
Lake Street Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $10 
Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026 
Alterity Therapeutics Secures Key US Patent for Lead Asset 
Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434
Your note
Sign in to keep a note on ATHE — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Morgan Stanley | 0.50% | 44,501 | 109.03K | Sep 29, 2024 |
| HB Wealth Management, LLC | 0.27% | 23,783 | 58.27K | Sep 29, 2024 |
| Susquehanna International Group, LLP | 0.16% | 13,932 | 34.13K | Sep 29, 2024 |
| UBS Group AG | 0.14% | 12,685 | 31.08K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.13% | 11,488 | 28.14K | Sep 29, 2024 |
| Twin Lakes Capital Management, LLC | 0.07% | 5,925 | 14.52K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.01% | 1,155 | 2.83K | Oct 30, 2024 |